Deals

Otsuka gobbles up more global rights for Akebia’s vadadustat, chipping in to a pot now worth $2B-plus

Late last year Otsuka stepped in with a deal worth more than a billion dollars to partner with Akebia on its experimental anemia drug vadadustat in the US market. But the pact evidently only whetted its appetite for more.

In a deal extension announced after the market closed on Tuesday, Otsuka came back to grab Europe, China, Russia and much of the rest of the world, paying another $208 million in committed capital covering $73 million upfront and $135 million to cover development costs. There’s also $657 million in potential milestones.

John Butler, Akebia

Otsuka, which clearly believes it’s linking on to a winner, added a 30% royalty — marking a rich payout for its partner, if the drug is approved.

The market loved these figures, with investors driving up Cambridge, MA-based Akebia’s stock by 28% in after-market trading.

Looking to partner up on the US market last December, Otsuka came in with $265 million in committed cash, including $125 million as an upfront payment with another $35 million due in early 2017 with over $105 million to help cover development costs and milestones reaching up to $765 million. Add in Akebia’s deal with Mitsubishi Tanabe for a group of Asian countries and the deal packages on this drug are worth more than $2 billion.

Committed funding for the drug — battling it out with a rival drug from FibroGen — has now hit $573 million.

Said John Butler, Akebia’s CEO:

We now have a single, strong collaborator for the two largest markets, the U.S. and Europe. This simplifies governance and decision making, maximising the efficiency of our global Phase 3 development programme and ultimately the commercialization of vadadustat. We are able to accomplish this while obtaining substantial funding for our vadadustat development programme and retaining significant long-term value for Akebia.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->